Showing results (181-190 of 232) with videos related to
Sort By:
Pageof 24
Archives of General Psychiatry|October 23, 1998
Morning vs evening light treatment of patients with winter depressionA J Lewy, V K Bauer, N L Cutler, et al.American Journal of Diseases of Children (1960)|January 1, 1992
Severe insulin resistance and diabetes mellitus in mandibuloacral dysplasiaG R Freidenberg, D L Cutler, M C Jones, et al.Current Medical Research and Opinion|August 25, 2004
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibeTeddy Kosoglou, Paul Statkevich, Jean-Charles Fruchart, et al.Journal of Cellular Physiology|September 1, 1993
Expression of transforming growth factor alpha antisense mRNA inhibits the estrogen-induced production of TGF alpha and estrogen-induced proliferation of estrogen-responsive human breast cancer cellsN J Kenney, T Saeki, M Gottardis, et al.Journal of Medical Virology|March 18, 2020
Development of hepatic pathology in GBV-B-infected red-bellied tamarins (Saguinus labiatus)Jessica M Dale, Simon P Hood, Ori Bowen, et al.Clinical Pharmacokinetics|April 28, 2020
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorDaryl J Fediuk, Gianluca Nucci, Vikas Kumar Dawra, et al.Clinical Pharmacology in Drug Development|May 23, 2018
Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy SubjectsVikas Kumar Dawra, David L Cutler, Susan Zhou, et al.European Journal of Clinical Pharmacology|February 9, 2012
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseTeddy Kosoglou, Walter K Kraft, Bharath Kumar, et al.FEBS Letters|June 24, 1991
Change in charge of an unvaried heme contact residue does not cause a major change of conformation in cytochrome cA G Thurgood, G J Pielak, R L Cutler, et al.European Journal of Clinical Pharmacology|October 5, 2011
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjectsTeddy Kosoglou, Larisa Reyderman, Claudia Kasserra, et al.Pageof 24